Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer

ANN ARBOR, MICH. -- A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or...

Read the whole article on Science Blog

More from Science Blog